13 April 2018 (Friday) - Oncologist Newsletter

The Oncologist newsletter arrived today. Loads of interesting stuff including an article on the treatment of lymphomas:

Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study

Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, Claudio Cerchione, Davide Nappi, Endri Mauro, Simone Ferrero, Salvatore Cuzzocrea, Michael Mian
Follicular lymphoma is the most common indolent lymphoma worldwide. Rituximab plus bendamustine (R-B) has been shown to improve outcome and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma; however, in clinical practice in many centers, R-CHOP is still the preferred treatment. This article reports the results of a study that assessed patients with follicular lymphoma grade 3A treated with either RCHOP or R-B in five European cancer centers.

No comments:

Post a comment